Exelixis (EXEL) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Twist Bioscience (TWST) has outperformed Exelixis (EXEL) over the past year, gaining 400.2% versus a gain of 47.5%. Over five years, EXEL leads with a +167.8% price change compared with +38.0% for TWST. Exelixis is the larger company by market cap ($14.56 billion vs $9.99 billion), about 1.5 times the size, while Twist Bioscience is growing revenue faster (+20.3% vs +7.0%).
Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus -20.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | TWST |
|---|---|---|
| Share price | $58.77 | $150.71 |
| Market cap | $14.56B | $9.99B |
| 1-day change | +0.56% | -3.17% |
| YTD return | +33.33% | +390.70% |
| 1-year return | +47.46% | +400.16% |
| 5-year return | +167.83% | +37.99% |
| P/E ratio (TTM) | 18.54 | — |
| Forward P/E | 13.86 | — |
| EPS (TTM) | $3.17 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $376.57M |
| Revenue growth (YoY) | +6.98% | +20.32% |
| Net income (latest FY) | $782.57M | $-77.67M |
| Gross margin | 96.39% | 50.72% |
| Operating margin | 37.59% | -36.18% |
| Net margin | 33.73% | -20.63% |
| 52-week high | $61.14 | $219.71 |
| 52-week low | $33.76 | $23.30 |
| Distance from 52-week high | -3.88% | -31.41% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -7.21% | -11.25% |
| Average volume | 2.34M | 1.99M |
| Shares outstanding | 247.78M | 66.30M |
| Employees | 1,077 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed EXEL by 352.7 percentage points over the past year.
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus -20.6 cents for Twist Bioscience.
- Twist Bioscience grew revenue faster in its latest fiscal year (+20.32% vs +6.98%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
EXEL vs TWST FAQ
Which is bigger, Exelixis or Twist Bioscience?
Exelixis (EXEL) is larger, with a market capitalization of $14.56B compared with $9.99B for Twist Bioscience (TWST).
Which stock has performed better over the past year, EXEL or TWST?
TWST returned +400.16% over the past 12 months, compared with +47.46% for EXEL (price return, excluding dividends). Past performance does not predict future results.
Are Exelixis and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.